2023-10-29 2024-10-28 false Capium Accounts Production 1.1 07593332 2023-10-29 2024-10-28 07593332 bus:AbridgedAccounts 2023-10-29 2024-10-28 07593332 bus:FRS102 2023-10-29 2024-10-28 07593332 bus:AuditExempt-NoAccountantsReport 2023-10-29 2024-10-28 07593332 bus:SmallCompaniesRegimeForAccounts 2023-10-29 2024-10-28 07593332 bus:PrivateLimitedCompanyLtd 2023-10-29 2024-10-28 07593332 2023-10-29 2024-10-28 07593332 2024-10-28 07593332 bus:RegisteredOffice 2023-10-29 2024-10-28 07593332 core:WithinOneYear 2024-10-28 07593332 core:AfterOneYear 2024-10-28 07593332 1 2023-10-29 2024-10-28 07593332 bus:Director1 2023-10-29 2024-10-28 07593332 bus:Director1 2024-10-28 07593332 bus:Director1 2022-10-29 2023-10-28 07593332 bus:Director2 2023-10-29 2024-10-28 07593332 bus:Director2 2024-10-28 07593332 bus:Director2 2022-10-29 2023-10-28 07593332 2022-10-29 07593332 bus:LeadAgentIfApplicable 2023-10-29 2024-10-28 07593332 2022-10-29 2023-10-28 07593332 2023-10-28 07593332 core:WithinOneYear 2023-10-28 07593332 core:AfterOneYear 2023-10-28 07593332 bus:EntityAccountantsOrAuditors 2022-10-29 2023-10-28 07593332 bus:OrdinaryShareClass1 2023-10-29 2024-10-28 07593332 bus:OrdinaryShareClass1 2024-10-28 07593332 bus:OrdinaryShareClass1 2022-10-29 2023-10-28 07593332 bus:OrdinaryShareClass1 2023-10-28 07593332 core:CostValuation core:Non-currentFinancialInstruments 2024-10-28 07593332 core:CostValuation core:Non-currentFinancialInstruments 2023-10-28 07593332 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-10-28 07593332 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-28 07593332 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-28 07593332 core:Non-currentFinancialInstruments 2024-10-28 07593332 core:Non-currentFinancialInstruments 2023-10-28 07593332 core:ShareCapital 2024-10-28 07593332 core:ShareCapital 2023-10-28 07593332 core:RetainedEarningsAccumulatedLosses 2024-10-28 07593332 core:RetainedEarningsAccumulatedLosses 2023-10-28 07593332 dpl:Item1 2023-10-29 07593332 dpl:Item1 2024-10-28 07593332 dpl:Item1 2022-10-29 07593332 dpl:Item1 2023-10-28 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 07593332
England and Wales
ORGEV LABORATORIES LTD
Abridged Accounts
Period of accounts Start date: 29 October 2023 End date: 28 October 2024

Orgev Laboratories Ltd Contents Page For the year ended 28 October 2024
Statement of financial position | 1
Notes to the financial statements | 2

Orgev Laboratories Ltd Statement of Financial Position As at 28 October 2024
| Notes | 2024 £ |  | 2023 £
--- | --- | --- | --- | ---
Current assets |  |  |
Stocks |  | 0 |  | 34,600
Cash at bank and in hand |  | 30 |  | 91
|  | 30 |  | 34,691
Creditors: amount falling due within one year |  | (45,650) |  | (22,850)
Net current assets |  | (45,620) |  | 11,841
Total assets less current liabilities |  | (45,620) |  | 11,841
Net assets |  | (45,620) |  | 11,841
Capital and reserves |  |  |
Called up share capital | 3 | 100 |  | 100
Profit and loss account |  | (45,720) |  | 11,741
Shareholders' funds |  | (45,620) |  | 11,841
For the year ended 28 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Directors' responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies. The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A). The financial statements were approved by the board of directors on 24 October 2025 and were signed on its behalf by:
------------------------------- Sebastien Thomas Eric Bai Director
1

Orgev Laboratories Ltd Notes to the Abridged Financial Statements For the year ended 28 October 2024
General Information Orgev Laboratories Ltd is a private company, limited by shares, registered in England and Wales, registration number 07593332, registration address Suit 2 The Exchange, Colworth Science Park, Bedford, MK44 1LQ. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies. The financial statements are prepared in sterling which is the functional currency of the company. Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
2. | Average number of employees Average number of employees during the year was 3 (2023 : 3).
3. | Share Capital
Allotted, called up and fully paid | 2024 £ |  | 2023 £
--- | --- | --- | ---
100 Class A shares of £1.00 each | 100 |  | 100
| 100 |  | 100
2